Serum uric acid level predicts adverse outcomes after myocardial revascularization or cardiac valve surgery

Abstract

Background

High levels of serum uric acid have been associated with adverse outcomes in cardiovascular diseases such as myocardial infarction and heart failure. The aim of the current study was to evaluate the prognostic role of serum uric acid levels in patients undergoing cardiac rehabilitation after myocardial revascularization and/or cardiac valve surgery.

Design

We performed an observational prospective cohort study.

Methods

The study included 1440 patients with available serum uric acid levels, prospectively followed for 50 ± 17 months. Mean age was 67 ± 11 years; 781 patients (54%) underwent myocardial revascularization, 474 (33%) cardiac valve surgery and 185 (13%) valve-plus-coronary artery by-pass graft surgery. The primary endpoints were overall and cardiovascular mortality while secondary end-points were combined major adverse cardiac and cerebrovascular events.

Results

Serum uric acid level mean values were 286 ± 95 µmol/l and elevated serum uric acid levels (≥360 µmol/l or 6 mg/dl) were found in 275 patients (19%). Overall mortality (hazard ratio = 2.1; 95% confidence interval: 1.5–3.0; p < 0.001), cardiovascular mortality (hazard ratio = 2.0; 95% confidence interval: 1.2–3.2; p = 0.004) and major adverse cardiac and cerebrovascular events rate (hazard ratio = 1.5; 95% confidence interval: 1.0–2.0; p = 0.019) were significantly higher in patients with elevated serum uric acid levels, even after adjustment for age, gender, arterial hypertension, diabetes, glomerular filtration rate, atrial fibrillation and medical therapy. Moreover, strong positive correlations between serum uric acid level and probability of overall mortality (p < 0.001), cardiovascular mortality (p < 0.001) and major adverse cardiac and cerebrovascular events (p = 0.003) were found.

Conclusions

Serum uric acid levels predict mortality and adverse cardiovascular outcome in patients undergoing myocardial revascularization and/or cardiac valve surgery even after the adjustment for age, gender, arterial hypertension, diabetes, glomerular filtration rate and medical therapy.

Keywords

Uric acid secondary cardiovascular prevention coronary artery disease cardiac valve disease

Get full access to this article

View all access options for this article.

References

Cannon

Stason

Demartini

et al.

Hyperuricemia in primary and renal hypertension. N Engl J Med 1966; 275: 457–464.

Ford

Cook

et al.

Serum concentrations of uric acid and the metabolic syndrome among US children and adolescents. Circulation 2007; 115: 2526–2532.

Tuttle

Short

Johnson

. Sex differences in uric acid and risk factors for coronary artery disease. Am J Cardiol 2001; 87: 1411–1414.

Lehto

Niskanen

Rönnemaa

et al.

Serum uric acid is a strong predictor of stroke in patients with non-insulin-dependent diabetes mellitus. Stroke 1998; 29: 635–639.

Schretlen

Inscore

Vannorsdall

et al.

Serum uric acid and brain ischemia in normal elderly adults. Neurology 2007; 69: 1418–1423.

Roberts

Bodnar

Lain

et al.

Uric acid is as important as proteinuria in identifying fetal risk in women with gestational hypertension. Hypertension 2005; 46: 1263–1269.

Siu

Leung

Tong

et al.

Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 2006; 47: 51–59.

Talaat

el-Sheikh

. The effect of mild hyperuricemia on urinary transforming growth factor beta and the progression of chronic kidney disease. Am J Nephrol 2007; 27: 435–440.

Feig

Johnson

. Hyperuricemia in childhood primary hypertension. Hypertension 2003; 42: 247–252.

10.

Niskanen

Laaksonen

Nyyssönen

et al.

Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: A prospective cohort study. Arch Intern Med 2004; 164: 1546–1551.

11.

Fang

Alderman

. Serum uric acid and cardiovascular mortality: The NHANES I epidemiologic follow-up study, 1971-1992. JAMA 2000; 283: 2404–2410.

12.

Alderman

Cohen

Madhavan

et al.

Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension 1999; 34: 144–150.

13.

Niskanen

Laaksonen

Lindström

et al.

Serum uric acid as a harbinger of metabolic outcome in subjects with impaired glucose tolerance: The Finnish Diabetes Prevention Study. Diabetes Care 2006; 29: 709–711.

14.

Iseki

Ikemiya

Inoue

et al.

Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis 2004; 44: 642–650.

15.

Levantesi

Marfisi

Franzosi

et al.

Uric acid: A cardiovascular risk factor in patients with recent myocardial infarction. Int J Cardiol 2013; 167: 262–269.

16.

Anker

Doehner

Rauchhaus

et al.

Uric acid and survival in chronic heart failure: Validation and application in metabolic, functional, and hemodynamic staging. Circulation 2003; 107: 1991–1997.

17.

Turker

Ekinozu

Turker

et al.

High levels of high-sensitivity C-reactive protein and uric acid can predict disease severity in patients with mitral regurgitation. Rev Port Cardiol 2014; 33: 699–706.

18.

Demir

Caglar

Ugurlucan

et al.

The relationship between severity of calcific aortic stenosis and serum uric acid levels. Angiology 2012; 63: 603–608.

19.

Gertler

Garn

Levine

. Serum uric acid in relation to age and physique in health and in coronary heart disease. Ann Intern Med 1951; 34: 1421–1431.

20.

Mercuro

Vitale

Cerquetani

et al.

Effect of hyperuricemia upon endothelial function in patients at increased cardiovascular risk. Am J Cardiol 2004; 94: 932–935.

21.

Saito

Saruta

Kondo

et al.

Serum uric acid and the renin-angiotensin system in hypertension. J Am Geriatr Soc 1978; 26: 241–247.

22.

Corry

Eslami

Yamamoto

et al.

Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin–angiotensin system. J Hypertens 2008; 26: 269–275.

23.

Ruggiero

Cherubini

Ble

et al.

Uric acid and inflammatory markers. Eur Heart J 2006; 27: 1174–1181.

24.

Kang

Park

Lee

et al.

Uric acid-induced C-reactive protein expression: Implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol 2005; 16: 3553–3562.

25.

Feig

Kang

Johnson

. Uric acid and cardiovascular risk. N Engl J Med 2008; 359: 1811–1821.

26.

Zalawadiya

Veeranna

Mallikethi-Reddy

et al.

Uric acid and cardiovascular disease risk reclassification: Findings from NHANES III. Eur J Prev Cardiol 2015; 4: 513–518.

27.

Gerber

Tanne

Medalie

et al.

Serum uric acid and long-term mortality from stroke, coronary heart disease and all causes. Eur J Cardiovasc Prev Rehabil 2006; 2: 193–198.

28.

Liese

Hense

Löwel

et al.

Association of serum uric acid with all-cause and cardiovascular disease mortality and incident myocardial infarction in the MONICA Augsburg cohort. World Health Organization Monitoring Trends and Determinants in Cardiovascular Diseases. Epidemiology 1999; 10: 391–397.

29.

Bos

Koudstaal

Hofman

et al.

Uric acid is a risk factor for myocardial infarction and stroke: The Rotterdam study. Stroke 2006; 37: 1503–1507.

30.

Hozawa

Folsom

Ibrahim

et al.

Serum uric acid and risk of ischemic stroke: The ARIC Study. Atherosclerosis 2006; 187: 401–407.

31.

White

Sofat

Hemani

et al.

Plasma urate concentration and risk of coronary heart disease: A Mendelian randomisation analysis. Lancet Diabetes Endocrinol 2016; 4: 327–336.

32.

Madsen

Muhlestein

Carlquist

et al.

Serum uric acid independently predicts mortality in patients with significant, angiographically defined coronary disease. Am J Nephrol 2005; 25: 45–49.

33.

Krishnan

Baker

Furst

et al.

Gout and the risk of acute myocardial infarction. Arthritis Rheum 2006; 54: 2688–2696.

34.

Von Lueder

Girerd

Atar

et al.

Serum uric acid is associated with mortality and heart failure hospitalizations in patients with complicated myocardial infarction: Findings from the High-Risk Myocardial Infarction Database Initiative. Eur J Heart Fail 2015; 17: 1144–1151.

35.

Rajamannan

Evans

Aikawa

et al.

Calcific aortic valve disease: Not simply a degenerative process: A review and agenda for research from the National Heart and Lung and Blood Institute Aortic Stenosis Working Group. Executive summary: Calcific aortic valve disease. Circulation 2011; 124: 1783–1791.

36.

Nidorf

Eikelboom

Budgeon

et al.

Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol 2013; 61: 404–410.